An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency. Issue 4 (29th April 2021)

• Record Type: Journal Article
• Authors: Martin, Erika J.; Nolte, Melinda E.; Kuhn, Janice; Schmidt, Nicole; Pfaff, Nils; Brophy, Donald F.
• Is Part Of: Haemophilia. Volume 27:Issue 4(2021)
• Page Start: 690
• Page End: 698
• Publication Date: 2021-04-29
• Subjects: coagulation -- haemophilia -- thrombin generation assay -- tissue factor pathway inhibitor -- whole blood clotting; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.14314
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract: Introduction: Tissue factor pathway inhibitor (TFPI) is an endogenous protein that inhibits the extrinsic (tissue factor) pathway and negatively regulates thrombin production during coagulation. Inhibiting TFPI may become a useful target for haemophilia drug development to allow greater thrombin generation without use of the intrinsic (contact) pathway. Aims: The in vitro effects of befovacimab, a humanized TFPI neutralizing antibody, were studied in whole blood and plasma samples from patients with severe FVIII deficiency. Methods: Blood and plasma obtained from participants was supplemented in vitro with befovacimab (0.5, 1, 5, 10 and 100 nM) or recombinant factor VIII (rFVIII) 5‐, 10‐ and 40% and analysed using rotational thromboelastometry (ROTEM), thrombin generation assay (TGA) and the dilute prothrombin time (dPT) assay. The in vitro coagulation effects of befovacimab were compared to samples supplemented with rFVIII. Results: Befovacimab induced consistent pro‐coagulant responses in ROTEM parameters including reduction in clotting times and increases in α‐angle; induced reductions in dPT clotting time; and improvements in TGA parameters (reduced lag time and increased thrombin generation parameters). There was a modest concentration‐dependent response generally from 0.5‐ to 10 nM, after which, the pharmacodynamic effect plateaued through the 100 nM concentration. Befovacimab concentrations of 5 to 10 nM showed pro‐coagulant activity comparable to blood samples supplemented with rFVIII 10–40%. Conclusions: Befovacimab has modest dose‐response effects from 0.5 to 10 nM with minimal improvement with higher concentrations. In vitro befovacimab blood concentrations of 5 to 10 nM had pro‐coagulant effects similar to blood supplemented with rFVIII 10‐ to 40%.